000176900 001__ 176900
000176900 005__ 20240229133723.0
000176900 0247_ $$2doi$$a10.1016/j.lanepe.2021.100063
000176900 0247_ $$2pmid$$apmid:34557810
000176900 0247_ $$2pmc$$apmc:PMC8454769
000176900 0247_ $$2altmetric$$aaltmetric:101080306
000176900 037__ $$aDKFZ-2021-02142
000176900 041__ $$aEnglish
000176900 082__ $$a610
000176900 1001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b0$$eFirst author$$udkfz
000176900 245__ $$aSocioeconomic deprivation and cancer survival in a metropolitan area: An analysis of cancer registry data from Hamburg, Germany.
000176900 260__ $$a[Amsterdam]$$bElsevier$$c2021
000176900 3367_ $$2DRIVER$$aarticle
000176900 3367_ $$2DataCite$$aOutput Types/Journal article
000176900 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692697174_16345
000176900 3367_ $$2BibTeX$$aARTICLE
000176900 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000176900 3367_ $$00$$2EndNote$$aJournal Article
000176900 500__ $$a#EA:C070#LA:C070#
000176900 520__ $$aFew studies have investigated socioeconomic inequalities within cities. Yet, such analyses are particularly important given the increasing international trend to urbanization. Here we investigated area-based socioeconomic inequalities in cancer survival in Hamburg, a port city in the North of Germany (population: 1.84 million people).Patients with a diagnosis of colorectal, lung, female breast, and prostate cancer in 2004-2018 (follow-up until 31.12.2018) and registered in the Hamburg cancer registry were included. Area-based socioeconomic deprivation on urban district level was assigned to the patients and grouped in five quintiles. Relative survival in 2014-2018 was calculated using the period approach. Trend analyses between 2004 and 2018 were conducted. Relative excess risks adjusted for age and stage were computed with model-based period analyses.For the 73,106 included patients, age-standardized 5-year relative survival in 2014-2018 decreased with increasing deprivation with significant differences between the most and least deprived group of 14·7 (prostate), 10·8 (colorectal), 8·0 (breast), and 2·5 (lung) percent units. Standardization by cancer stage decreased the difference for prostate cancer to 8·5 percent units and for breast cancer to 3·6 percent units but had only a minor effect for colorectal and lung cancer. Similar socioeconomic inequalities were already present in 2004-08.Strong socioeconomic inequalities in cancer survival were observed in Hamburg, which could be partly explained by differences in the stage distribution. Further research including information on screening participation as well as information on cancer care are important to further understand and finally overcome these inequalities.German Cancer Aid.
000176900 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000176900 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000176900 7001_ $$aErb, Cynthia$$b1
000176900 7001_ $$aNennecke, Alice$$b2
000176900 7001_ $$0P:(DE-He78)a79a61dd9934f6115f9383fd1dc21d76$$aFinke, Isabelle$$b3$$udkfz
000176900 7001_ $$aPritzkuleit, Ron$$b4
000176900 7001_ $$aHolleczek, Bernd$$b5
000176900 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$eLast author$$udkfz
000176900 7001_ $$aGroup, German Cancer Survival Working$$b7$$eCollaboration Author
000176900 773__ $$0PERI:(DE-600)3055963-7$$a10.1016/j.lanepe.2021.100063$$gVol. 4, p. 100063 -$$p100063$$tThe lancet / Regional health. Europe$$v4$$x2666-7762$$y2021
000176900 909CO $$ooai:inrepo02.dkfz.de:176900$$pVDB
000176900 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000176900 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a79a61dd9934f6115f9383fd1dc21d76$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000176900 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000176900 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000176900 9141_ $$y2021
000176900 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-12-02T13:40:13Z
000176900 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-12-02T13:40:13Z
000176900 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-12-02T13:40:13Z
000176900 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-25
000176900 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-25
000176900 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000176900 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000176900 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000176900 980__ $$ajournal
000176900 980__ $$aVDB
000176900 980__ $$aI:(DE-He78)C070-20160331
000176900 980__ $$aI:(DE-He78)C120-20160331
000176900 980__ $$aI:(DE-He78)HD01-20160331
000176900 980__ $$aUNRESTRICTED